Evotec stock: RBC keeps EUR 10.00 target for Evotec stock

Published on 10/21/2026 at 17:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec expects EUR 465.00 million in nine-month revenue for 2026. Evotec stock costs EUR 2.77 on October 21, 2026, up 1.95 percent versus Xetra close.

Revenue and reporting date

RBC kept its Outperform rating and EUR 10.00 target on October 14, 2026.
Evotec expected EUR 465.00 million in revenue for the first nine months of 2026.
Evotec stood at EUR 2.77 at Tradegate on October 21, 2026, 1.95 percent above the Xetra close of October 20, 2026.
Evotec planned to publish third-quarter results on November 5, 2026.

Bunte Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Pop-Art-Comic-Szene mit Wissenschaftler und Reagenzglas symbolisiert lebendig die Forschungswelt von Evotec SE, ISIN DE0005664809, Illustration mit AI erstellt.

RBC kept its Outperform rating and a EUR 10.00 price target for Evotec on October 14, 2026, after the company reported preliminary nine-month figures above market expectations, according to MarketScreener. The substitute Tradegate quote stood at EUR 2.77 on October 21, 2026 at 10:06 a.m. CEST, up 1.95 percent versus the Xetra close of October 20, 2026.

Revenue sets the next benchmark

Evotec expected Group revenue of EUR 465.00 million for the first nine months of 2026 and an adjusted Group EBITDA loss of EUR 42.80 million. RTTNews reported on October 14, 2026 that both figures came in above market expectations, with the variance mainly linked to the timing of consensus estimates.

The company reaffirmed full-year 2026 revenue guidance of EUR 570.00 million to EUR 610.00 million and adjusted EBITDA guidance of a loss between EUR 70.00 million and EUR 105.00 million, according to RTTNews.

Tradegate quote remains below the target

The EUR 2.77 substitute quote was 1.95 percent above the EUR 2.72 Xetra close of October 20, 2026. That daily comparison places the market price well below RBC's EUR 10.00 target, while the negative adjusted EBITDA guidance keeps profitability in view as a central valuation issue.

Evotec develops drug candidates and related services for pharmaceutical and biotechnology partners. Its investor-relations materials describe a model built around research alliances, data-driven drug discovery and the Just - Evotec Biologics platform.

November 5 is the next date

Evotec planned to publish its third-quarter and nine-month 2026 results on November 5, 2026, RTTNews reported on October 14, 2026. That release should provide the first complete review of the EUR 465.00 million preliminary revenue figure and the adjusted EBITDA loss.

Stock stays tied to execution

For investors, the key tension is clear: the preliminary revenue figure exceeded expectations, but the full-year guidance still includes a substantial adjusted EBITDA loss. The EUR 10.00 RBC target therefore depends on stronger execution than the current EUR 2.77 Tradegate quote implies.